// App-Quantinova.ai

Tu1793 : CONCOMITANT IMMUNOMODULATOR IS ASSOCIATED WITH A DECREASED RISK OF ANTI-TNF DISCONTINUATION AND SUBSTITUTION: A POPULATION BASED STUDY

Researchers

Presenter

  • Charles N. Bernstein

Principal Investigators

  • Harminder Singh

  • Jennifer L. Jones

  • Kevan Jacobson

  • Sanjay K. Murthy

  • Alain Bitton

  • Zoann Nugent

  • Aruni Tennakoon

  • Stella Leung

  • Lisa Lix

  • Eric I. Benchimol

  • Geoffrey C. Nguyen

  • Gilaad Kaplan

  • Juan-Nicolas Pena-Sanchez

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • University of Ottawa, Ottawa, ON, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Montreal University, Montreal, QC, Canada

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • University of Toronto, Toronto, ON, Canada

  • University of Mantioba, Winnipeg, MB, Canada

  • University of Ottawa, Ottawa, ON, Canada

  • University of British Columbia, Vancouver, British Columbia, Canada.

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Infliximab

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved